IDH1 and cancer: Ivosidenib is an oral anti-cancer agent that is well-recognized for its ability to target the mutant IDH1 enzyme to reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), consequently alleviating its oncogenic effects, including epigenetic alteration and metabolism reprograming [32,33].